After an extended struggle Mark Emalfarb, the founder of Dyadic has regained control of the firm. He was originally ousted by the board after an accounting scandal at a foreign subsidiary. By forming a coalition with other shareholders, representing a majority of the company’s shares, Emalfarb was able to dismiss the board members who had ousted him in a court-ordered annual shareholder meeting. Read more →
Guest content from John Avellanet, managing director and principal of Cerulean Associates:
For those attending BIO2008, I’ll be speaking on Friday morning:
Title: Scientific Communications – Trends and Liabilities
Track: Public Relations/Investor Relations
Date and Time: Friday, June 20 9:00 AM – 10:30 AM
Hope to see you there!
For those attending BIO2008 in San Diego this year, I’ll be signing my books in the BIO bookstore on Wednesday June 18th from 10-11. There will also be a limited number of free copies of the Journal of Commercial Biotechnology, so be sure and show up early!
Courtesy of DrugPatentWatch.com:
*Drugs may be covered by multiple patents
| Tradename | Applicant | Generic Name | Patent Number | Patent Expiration |
| ADALAT CC | Bayer Pharms | nifedipine | 4,892,741 | Jun 8, 2008 |
| CAVERJECT IMPULSE | Pharmacia And Upjohn | alprostadil | 4,968,299 | Jun 28, 2008 |
| EFFEXOR | Wyeth Pharms Inc | venlafaxine hydrochloride | 4,535,186 | Jun 13, 2008 |
| EFFEXOR XR | Wyeth Pharms Inc | venlafaxine hydrochloride | 4,535,186 | Jun 13, 2008 |
| GENOTROPIN | Pharmacia And Upjohn | somatropin recombinant | 4,968,299 | Jun 28, 2008 |
| GENOTROPIN PRESERVATIVE FREE | Pharmacia And Upjohn | somatropin recombinant | 4,968,299 | Jun 28, 2008 |
| NICODERM CQ | Sanofi Aventis Us | nicotine | 5,004,610 | Jun 14, 2008 |
| NICODERM CQ | Sanofi Aventis Us | nicotine | 5,342,623 | Jun 14, 2008 |
| NICODERM CQ | Sanofi Aventis Us | nicotine | 5,344,656 | Jun 14, 2008 |
| NICODERM CQ | Sanofi Aventis Us | nicotine | 5,364,630 | Jun 14, 2008 |
| NICODERM CQ | Sanofi Aventis Us | nicotine | 5,462,745 | Jun 14, 2008 |
| NICODERM CQ | Sanofi Aventis Us | nicotine | 5,633,008 | Jun 14, 2008 |
| NICODERM CQ | Sanofi Aventis Us | nicotine | 6,165,497 | Jun 14, 2008 |
| PREVACID | Tap Pharm | lansoprazole | 5,026,560 | Jun 25, 2008 |
| RISPERDAL | Janssen Pharma | risperidone | 4,804,663 | Jun 29, 2008 |
| RISPERDAL CONSTA | Janssen Pharma | risperidone | 4,804,663 | Jun 29, 2008 |
| SONATA | King Pharms | zaleplon | 4,626,538 | Jun 6, 2008 |
| SULAR | Sciele Pharma Inc | nisoldipine | 4,892,741 | Jun 8, 2008 |
| TESTIM | Auxilium Pharms | testosterone | 5,023,252 | Jun 11, 2008 |
Courtesy of DrugPatentWatch.com
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
Recent Comments